drugset / Trial / NCT00892281

ORCA - Oracea® for Rosacea: A Community-based Assessment

NCT00892281

Phase 4 Completed 1421 enrolled Galderma R&D
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.

Timeline

Start
2009-04
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 40 mg

Indications